Nello Mainolfi - 03 Jun 2025 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
03 Jun 2025
Net transactions value
-$1,407,600
Form type
4
Filing time
03 Jun 2025, 18:30:05 UTC
Previous filing
03 Mar 2025
Next filing
16 Sep 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mainolfi Nello Chief Executive Officer, Director C/O KYMERA THERAPEUTICS, INC., 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN /s/ Bruce Jacobs, as Attorney-in-Fact 03 Jun 2025 0001821189

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $62,400 +30,000 +4.5% $2.08 690,482 03 Jun 2025 Direct F1, F2
transaction KYMR Common Stock Sale $1,470,000 -30,000 -4.3% $49.00 660,482 03 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -30,000 -6.1% $0.000000 465,559 03 Jun 2025 Common Stock 30,000 $2.08 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.
F2 This number includes 523 shares acquired under the Registrant's employee stock purchase plan on June 2, 2025.
F3 The shares underlying this stock option are fully vested and exercisable.